Why is epigenetics important in understanding the pathogenesis of inflammatory musculoskeletal diseases?

Arthritis Research and Therapy

Volumn 15, Issue 2, 2013, Pages

  Oppermann, Udo ^a,b  

^a NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HISTONE; HISTONE DEACETYLASE INHIBITOR; UNTRANSLATED RNA;

AUTOIMMUNE DISEASE; BIOCHEMISTRY; BONE CANCER; CHROMATIN; DNA METHYLATION; DNA MODIFICATION; DNA SEQUENCE; EPIGENETICS; HISTONE MODIFICATION; HOMEOSTASIS; HUMAN; INFLAMMATORY DISEASE; INFLAMMATORY MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL DISEASE; NEOPLASM; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PHENOTYPE; REVIEW; RHEUMATOID ARTHRITIS; GENETIC EPIGENESIS; GENETICS;

AUTOIMMUNE DISEASES; EPIGENESIS, GENETIC; HUMANS; MUSCULOSKELETAL DISEASES;

EID: 84876100588     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4186     Document Type: Review

References (91)

1. Waddington CH. The Strategy of the Genes 1957, London: Allen & Unwin.
2. Bird A. Perceptions of epigenetics. Nature 2007, 447:396-398. 10.1038/nature05913, 17522671.
3. Ptashne M. On the use of the word 'epigenetic'. Curr Biol 2007, 17:R233-R236. 10.1016/j.cub.2007.02.030, 17407749.
4. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev 2009, 23:781-783. 10.1101/gad.1787609, 19339683.
5. Alexander RP, Fang G, Rozowsky J, Snyder M, Gerstein MB. Annotating non-coding regions of the genome. Nat Rev Genet 2010, 11:559-571. 10.1038/nrg2814, 20628352.
6. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011, 12:861-874.
7. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB, Zhang X, Wang L, Issner R, Coyne M, Ku M, Durham T, Kellis M, Bernstein BE. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 2011, 473:43-49. 10.1038/nature09906, 3088773, 21441907.
8. Feinberg AP. Epigenomics reveals a functional genome anatomy and a new approach to common disease. Nat Biotechnol 2010, 28:1049-1052. 10.1038/nbt1010-1049, 2956605, 20944596.
9. Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489:57-74. 10.1038/nature11247, 3439153, 22955616.
10. Thurman RE, Rynes E, Humbert R, Vierstra J, Maurano MT, Haugen E, Sheffield NC, Stergachis AB, Wang H, Vernot B, Garg K, John S, Sandstrom R, Bates D, Boatman L, Canfield TK, Diegel M, Dunn D, Ebersol AK, Frum T, Giste E, Johnson AK, Johnson EM, Kutyavin T, Lajoie B, Lee BK, Lee K, London D, Lotakis D, Neph S, et al. The accessible chromatin landscape of the human genome. Nature 2012, 489:75-82. 10.1038/nature11232, 22955617.
11. Jenuwein T, Allis CD. Translating the histone code. Science 2001, 293:1074-1080. 10.1126/science.1063127, 11498575.
12. Sanyal A, Lajoie BR, Jain G, Dekker J. The long-range interaction landscape of gene promoters. Nature 2012, 489:109-113. 10.1038/nature11279, 3555147, 22955621.
13. Cai S, Lee CC, Kohwi-Shigematsu T. SATB1 packages densely looped, transcriptionally active chromatin for coordinated expression of cytokine genes. Nat Genet 2006, 38:1278-1288. 10.1038/ng1913, 17057718.
14. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012, 13:484-492. 10.1038/nrg3230, 22641018.
15. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011, 25:1010-1022. 10.1101/gad.2037511, 3093116, 21576262.
16. Stadler MB, Murr R, Burger L, Ivanek R, Lienert F, Scholer A, van Nimwegen E, Wirbelauer C, Oakeley EJ, Gaidatzis D, Tiwari VK, Schubeler D. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature 2011, 480:490-495.
17. Illingworth RS, Gruenewald-Schneider U, Webb S, Kerr AR, James KD, Turner DJ, Smith C, Harrison DJ, Andrews R, Bird AP. Orphan CpG islands identify numerous conserved promoters in the mammalian genome. PLoS Genet 2010, 6:e1001134. 10.1371/journal.pgen.1001134, 2944787, 20885785.
18. Lujambio A, Portela A, Liz J, Melo SA, Rossi S, Spizzo R, Croce CM, Calin GA, Esteller M. CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene 2010, 29:6390-6401. 10.1038/onc.2010.361, 3007676, 20802525.
19. De Carvalho DD, Sharma S, You JS, Su SF, Taberlay PC, Kelly TK, Yang X, Liang G, Jones PA. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 2012, 21:655-667. 10.1016/j.ccr.2012.03.045, 22624715.
20. Taberlay PC, Jones PA. DNA methylation and cancer. Prog Drug Res 2011, 67:1-23.
21. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4:143-153.
22. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92. 10.1038/301089a0, 6185846.
23. Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 1989, 83:155-158. 10.1007/BF00286709, 2550354.
24. Auclair G, Weber M. Mechanisms of DNA methylation and demethylation in mammals. Biochimie 2012, 94:2202-2211. 10.1016/j.biochi.2012.05.016, 22634371.
25. Liu Y, Aryee MJ, Padyukov L, Fallin MD, Hesselberg E, Runarsson A, Reinius L, Acevedo N, Taub M, Ronninger M, Shchetynsky K, Scheynius A, Kere J, Alfredsson L, Klareskog L, Ekstrom TJ, Feinberg AP. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol 2013, 31:142-147. 10.1038/nbt.2487, 23334450.
26. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27. 10.1016/j.cell.2012.06.013, 22770212.
27. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 2012, 13:343-357.
28. Ng SS, Yue WW, Oppermann U, Klose RJ. Dynamic protein methylation in chromatin biology. Cell Mol Life Sci 2009, 66:407-422. 10.1007/s00018-008-8303-z, 2794343, 18923809.
29. De Santa F, Narang V, Yap ZH, Tusi BK, Burgold T, Austenaa L, Bucci G, Caganova M, Notarbartolo S, Casola S, Testa G, Sung WK, Wei CL, Natoli G. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J 2009, 28:3341-3352. 10.1038/emboj.2009.271, 2752025, 19779457.
30. De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G, Natoli G. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 2007, 130:1083-1094. 10.1016/j.cell.2007.08.019, 17825402.
31. Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bountra C, Bridges A, Diallo H, Eberhard D, Hutchinson S, Jones E, Katso R, Leveridge M, Mander PK, Mosley J, Ramirez-Molina C, Rowland P, Schofield CJ, Sheppard RJ, Smith JE, Swales C, Tanner R, Thomas P, Tumber A, Drewes G, Oppermann U, Patel DJ, Lee K, et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012, 488:404-408. 10.1038/nature11262, 22842901.
32. Natoli G. Specialized chromatin patterns in the control of inflammatory gene expression. Curr Top Microbiol Immunol 2011, 349:61-72. 10.1007/82_2010_106, 20857270.
33. Stender JD, Pascual G, Liu W, Kaikkonen MU, Do K, Spann NJ, Boutros M, Perrimon N, Rosenfeld MG, Glass CK. Control of proinflammatory gene programs by regulated trimethylation and demethylation of histone H4K20. Mol Cell 2012, 48:28-38. 10.1016/j.molcel.2012.07.020, 22921934.
34. Sinha KM, Yasuda H, Coombes MM, Dent SY, de Crombrugghe B. Regulation of the osteoblast-specific transcription factor Osterix by NO66, a Jumonji family histone demethylase. EMBO J 2009, 29:68-79. 2780536, 19927124.
35. Yasui T, Hirose J, Tsutsumi S, Nakamura K, Aburatani H, Tanaka S. Epigenetic regulation of osteoclast differentiation: possible involvement of Jmjd3 in the histone demethylation of Nfatc1. J Bone Miner Res 2011, 26:2665-2671. 10.1002/jbmr.464, 21735477.
36. Ye L, Fan Z, Yu B, Chang J, Al Hezaimi K, Zhou X, Park NH, Wang CY. Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs. Cell Stem Cell 2012, 11:50-61. 10.1016/j.stem.2012.04.009, 22770241.
37. Blackledge NP, Klose RJ. Histone lysine methylation: an epigenetic modification. Epigenomics 2010, 2:151-161. 10.2217/epi.09.42, 22122751.
38. Blomen VA, Boonstra J. Stable transmission of reversible modifications: maintenance of epigenetic information through the cell cycle. Cell Mol Life Sci 2010, 68:27-44. 3015210, 20799050.
39. Vaissiere T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 2008, 659:40-48. 10.1016/j.mrrev.2008.02.004, 18407786.
40. Carr SM, Munro S, Kessler B, Oppermann U, La Thangue NB. Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein. EMBO J 2010, 30:317-327. 3025457, 21119616.
41. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL. p53 is regulated by the lysine demethylase LSD1. Nature 2007, 449:105-108. 10.1038/nature06092, 17805299.
42. Levy D, Kuo AJ, Chang Y, Schaefer U, Kitson C, Cheung P, Espejo A, Zee BM, Liu CL, Tangsombatvisit S, Tennen RI, Kuo AY, Tanjing S, Cheung R, Chua KF, Utz PJ, Shi X, Prinjha RK, Lee K, Garcia BA, Bedford MT, Tarakhovsky A, Cheng X, Gozani O. Lysine methylation of the NF-κB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-κB signaling. Nat Immunol 2010, 12:29-36. 3074206, 21131967.
43. Lu T, Jackson MW, Wang B, Yang M, Chance MR, Miyagi M, Gudkov AV, Stark GR. Regulation of NF-κB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci USA 2010, 107:46-51. 10.1073/pnas.0912493107, 2806709, 20080798.
44. Ceribelli A, Nahid MA, Satoh M, Chan EK. MicroRNAs in rheumatoid arthritis. FEBS Lett 2011, 585:3667-3674. 10.1016/j.febslet.2011.05.020, 3168677, 21600203.
45. Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA. miRNAs and related polymorphisms in rheumatoid arthritis susceptibility. Autoimmun Rev 2011, 11:636-641.
46. Kurowska-Stolarska M, Alivernini S, Ballantine LE, Asquith DL, Millar NL, Gilchrist DS, Reilly J, Ierna M, Fraser AR, Stolarski B, McSharry C, Hueber AJ, Baxter D, Hunter J, Gay S, Liew FY, McInnes IB. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci USA 2011, 108:11193-11198. 10.1073/pnas.1019536108, 3131377, 21690378.
47. Pan W, Zhu S, Yuan M, Cui H, Wang L, Luo X, Li J, Zhou H, Tang Y, Shen N. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol 2010, 184:6773-6781. 10.4049/jimmunol.0904060, 20483747.
48. Baxter D, McInnes IB, Kurowska-Stolarska M. Novel regulatory mechanisms in inflammatory arthritis: a role for microRNA. Immunol Cell Biol 2012, 90:288-292. 10.1038/icb.2011.114, 22249200.
49. Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA. A polymorphism in the 3'-UTR of interleukin-1 receptor-associated kinase (IRAK1), a target gene of miR-146a, is associated with rheumatoid arthritis susceptibility. Joint Bone Spine 2010, 77:411-413. 10.1016/j.jbspin.2010.05.013, 20870441.
50. Klug M, Heinz S, Gebhard C, Schwarzfischer L, Krause SW, Andreesen R, Rehli M. Active DNA demethylation in human postmitotic cells correlates with activating histone modifications, but not transcription levels. Genome Biol 2010, 11:R63. 10.1186/gb-2010-11-6-r63, 2911111, 20565882.
51. Ushijima T, Watanabe N, Okochi E, Kaneda A, Sugimura T, Miyamoto K. Fidelity of the methylation pattern and its variation in the genome. Genome Res 2003, 13:868-874. 10.1101/gr.969603, 430912, 12727906.
52. Carson WF, Cavassani KA, Dou Y, Kunkel SL. Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics 2011, 6:273-283. 10.4161/epi.6.3.14017, 3092675, 21048427.
53. Javierre BM, Hernando H, Ballestar E. Environmental triggers and epigenetic deregulation in autoimmune disease. Discov Med 2011, 12:535-545.
54. Lim U, Song MA. Dietary and lifestyle factors of DNA methylation. Methods Mol Biol 2012, 863:359-376. 10.1007/978-1-61779-612-8_23, 22359306.
55. McEwen BS. Understanding the potency of stressful early life experiences on brain and body function. Metabolism 2008, 57(Suppl 2):S11-S15. 2567059, 18803958.
56. Craddock N, Hurles ME, Cardin N, Pearson RD, Plagnol V, Robson S, Vukcevic D, Barnes C, Conrad DF, Giannoulatou E, Holmes C, Marchini JL, Stirrups K, Tobin MD, Wain LV, Yau C, Aerts J, Ahmad T, Andrews TD, Arbury H, Attwood A, Auton A, Ball SG, Balmforth AJ, Barrett JC, Barroso I, Barton A, Bennett AJ, Bhaskar S, Blaszczyk K, et al. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature 2010, 464:713-720. 10.1038/nature08979, 2892339, 20360734.
57. Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, Oppermann U, Dilthey A, Pirinen M, Stone MA, Appleton L, Moutsianas L, Leslie S, Wordsworth T, Kenna TJ, Karaderi T, Thomas GP, Ward MM, Weisman MH, Farrar C, Bradbury LA, Danoy P, Inman RD, Maksymowych W, Gladman D, Rahman P, Morgan A, Marzo-Ortega H, Bowness P, Gaffney K, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 2011, 43:761-767. 10.1038/ng.873, 21743469.
58. Anway MD, Cupp AS, Uzumcu M, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 2005, 308:1466-1469. 10.1126/science.1108190, 15933200.
59. Sutherland JE, Costa M. Epigenetics and the environment. Ann N Y Acad Sci 2003, 983:151-160. 10.1111/j.1749-6632.2003.tb05970.x, 12724220.
60. Waterland RA, Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 2003, 23:5293-5300. 10.1128/MCB.23.15.5293-5300.2003, 165709, 12861015.
61. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, Dymov S, Szyf M, Meaney MJ. Epigenetic programming by maternal behavior. Nat Neurosci 2004, 7:847-854. 10.1038/nn1276, 15220929.
62. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007, 447:433-440. 10.1038/nature05919, 17522677.
63. Petronis A. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. Nature 2010, 465:721-727. 10.1038/nature09230, 20535201.
64. Klareskog L, Padyukov L, Alfredsson L. Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol 2007, 19:49-54. 10.1097/BOR.0b013e32801127c8, 17143096.
65. Ishida K, Kobayashi T, Ito S, Komatsu Y, Yokoyama T, Okada M, Abe A, Murasawa A, Yoshie H. Interleukin-6 gene promoter methylation in rheumatoid arthritis and chronic periodontitis. J Periodontol 2012, 83:917-925. 10.1902/jop.2011.110356, 22122521.
66. Lopez-Pedrera C, Perez-Sanchez C, Ramos-Casals M, Santos-Gonzalez M, Rodriguez-Ariza A, Cuadrado MJ. Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions. Clin Dev Immunol 2012, 2012:974648. 3173726, 21941583.
67. De Santis M, Selmi C. The therapeutic potential of epigenetics in autoimmune diseases. Clin Rev Allergy Immunol 2012, 42:92-101. 10.1007/s12016-011-8293-8, 22161696.
68. Ospelt C, Reedquist KA, Gay S, Tak PP. Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis. Autoimmun Rev 2011, 10:519-524. 10.1016/j.autrev.2011.04.001, 21497675.
69. Liu CC, Fang TJ, Ou TT, Wu CC, Li RN, Lin YC, Lin CH, Tsai WC, Liu HW, Yen JH. Global DNA methylation, DNMT1, and MBD2 in patients with rheumatoid arthritis. Immunol Lett 2010, 135:96-99.
70. Liu Y, Chen Y, Richardson B. Decreased DNA methyltransferase levels contribute to abnormal gene expression in 'senescent' CD4(+)CD28(-) T cells. Clin Immunol 2009, 132:257-265. 10.1016/j.clim.2009.03.529, 2710420, 19394279.
71. Nile CJ, Read RC, Akil M, Wilson AG. Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum 2008, 58:2686-2693. 10.1002/art.23758, 18759290.
72. Zhang Y, Zhao M, Sawalha AH, Richardson B, Lu Q. Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus. J Autoimmun 2013,
73. Karouzakis E, Gay RE, Gay S, Neidhart M. Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nat Rev Rheumatol 2009, 5:266-272.
74. Karouzakis E, Gay RE, Michel BA, Gay S, Neidhart M. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009, 60:3613-3622. 10.1002/art.25018, 19950268.
75. Nakano K, Boyle DL, Firestein GS. Regulation of DNA methylation in rheumatoid arthritis synoviocytes. J Immunol 2013, 190:1297-1303. 10.4049/jimmunol.1202572, 23277489.
76. Nakano K, Whitaker JW, Boyle DL, Wang W, Firestein GS. DNA methylome signature in rheumatoid arthritis. Ann Rheum Dis 2012, 72:110-117.
77. Choo QY, Ho PC, Tanaka Y, Lin HS. Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-κB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatology (Oxford) 2010, 49:1447-1460. 10.1093/rheumatology/keq108, 20421217.
78. Vojinovic J, Damjanov N. HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol Med 2011, 17:397-403. 3105145, 21308151.
79. Vojinovic J, Damjanov N, D'Urzo C, Furlan A, Susic G, Pasic S, Iagaru N, Stefan M, Dinarello CA. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2011, 63:1452-1458. 10.1002/art.30238, 21538322.
80. Richardson B. DNA methylation and autoimmune disease. Clin Immunol 2003, 109:72-79. 10.1016/S1521-6616(03)00206-7, 14585278.
81. Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, Rovere-Querini P, Herrmann M, Voll RE. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008, 205:3007-3018. 10.1084/jem.20081165, 2605236, 19064698.
82. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB, Esmon NL, Lupu F, Esmon CT. Extracellular histones are major mediators of death in sepsis. Nat Med 2009, 15:1318-1321. 10.1038/nm.2053, 2783754, 19855397.
83. Austenaa L, Barozzi I, Chronowska A, Termanini A, Ostuni R, Prosperini E, Stewart AF, Testa G, Natoli G. The histone methyltransferase Wbp7 controls macrophage function through GPI glycolipid anchor synthesis. Immunity 2012, 36:572-585. 10.1016/j.immuni.2012.02.016, 22483804.
84. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H, White J, Kirilovsky J, Rice CM, Lora JM, Prinjha RK, Lee K, Tarakhovsky A. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123. 10.1038/nature09589, 21068722.
85. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917. 10.1016/j.cell.2011.08.017, 3187920, 21889194.
86. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073. 10.1038/nature09504, 3010259, 20871596.
87. Belkina AC, Denis GV. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer 2012, 12:465-477. 10.1038/nrc3256, 22722403.
88. Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M, Kumagai S. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2009, 36:1580-1589. 10.3899/jrheum.081115, 19531758.
89. Chen WP, Bao JP, Hu PF, Feng J, Wu LD. Alleviation of osteoarthritis by Trichostatin A, a histone deacetylase inhibitor, in experimental osteoarthritis. Mol Biol Rep 2010, 37:3967-3972. 10.1007/s11033-010-0055-9, 20237852.
90. Saito T, Nishida K, Furumatsu T, Yoshida A, Ozawa M, Ozaki T. Histone deacetylase inhibitors suppress mechanical stress-induced expression of RUNX-2 and ADAMTS-5 through the inhibition of the MAPK signaling pathway in cultured human chondrocytes. Osteoarthritis Cartilage 2012, 21:165-174.
91. Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T, Pillus L, Reinberg D, Shi Y, Shiekhattar R, Shilatifard A, Workman J, Zhang Y. New nomenclature for chromatin-modifying enzymes. Cell 2007, 131:633-636. 10.1016/j.cell.2007.10.039, 18022353.